Escalating prevalence of valve heart diseases
In the Middle East and Africa, valvular heart diseases are becoming prevalent due to a mix of rheumatic and degenerative causes. In many African countries, rheumatic fever still contributes to mitral and aortic valve damage, particularly among younger populations. Meanwhile, in Gulf and urban centers, lifestyle-related cardiovascular risk factors such as hypertension, diabetes, and obesity are leading to a rise in age-related valve degeneration. Improved awareness and diagnostic capabilities, including more widespread echocardiography and referral networks, have resulted in more patients being diagnosed and considered for intervention.
Access to traditional open-heart surgery is often limited in large parts of Africa due to the scarcity of specialized cardiac centers, long distances, and limited surgical resources. In the Middle East, while advanced cardiac care exists in urban hubs, patient demand for less invasive procedures is rising, especially among high-risk and elderly populations. Transcatheter heart valves provide an effective alternative, offering shorter recovery times, reduced procedural risk, and lower hospital resource use. This combination of growing disease prevalence and treatment gaps is driving the adoption of minimally invasive solutions in the region.
Government programs and international collaborations are also enhancing the region's ability to treat valvular heart diseases. Training initiatives, the establishment of specialized cardiac units, and public health campaigns are improving diagnosis and treatment pathways. With patient awareness rising and interventional expertise growing, the increasing burden of valvular heart disease is a key driver for the Middle East & Africa transcatheter heart valve market.
Development of mitral & tricuspid valve therapies
Historically, transcatheter interventions in the MEA have focused on aortic valve disease, but there is an increasing interest in treating mitral and tricuspid valve disorders. Improved imaging techniques, growing cardiology expertise in major hospitals, and the introduction of specialized devices are allowing physicians to evaluate and treat these complex valve conditions. Urban centers in South Africa, Egypt, Saudi Arabia, and the UAE are performing these procedures, creating a significant market opportunity for expansion beyond aortic valve interventions.
Patients with mitral and tricuspid valve disease often face higher procedural risk due to age or comorbidities, and surgical options are limited outside major cities. Minimally invasive transcatheter therapies allow these patients to receive effective treatment with lower complication rates and shorter hospital stays. The availability of these therapies in specialized urban centers also encourages referral from regional hospitals, increasing patient access and awareness.
For device manufacturers and healthcare providers, this presents a clear opportunity to grow the transcatheter heart valve market. By supporting training programs, procedural guidance, and local clinical collaborations, companies can help expand the adoption of mitral and tricuspid interventions. As physician confidence and patient demand increase, these applications are expected to become a key growth segment in the Middle East & Africa.
